Scholar Rock Holding (SRRK) Cash from Financing Activities (2017 - 2026)

Scholar Rock Holding's (SRRK) quarterly Cash from Financing Activities came in at $193.8 million in Q1 2026, up 4548.26% year-on-year from $4.2 million in Q1 2025, and up 164.42% quarter-over-quarter from $73.3 million in Q4 2025.

Scholar Rock Holding (SRRK) Cash from Financing Activities (2017 - 2026) Analysis & Trends

Scholar Rock Holding's Cash from Financing Activities history runs 10 years deep, the most recent figure standing at $193.8 million for Q1 2026.

  • On a quarterly basis, Cash from Financing Activities rose 4548.26% year-over-year to $193.8 million in Q1 2026; TTM through Mar 2026 was $418.0 million, a 19.2% increase from a year earlier, with the FY2025 full-year figure at $228.4 million, down 35.3% from the prior year.
  • Cash from Financing Activities improved to $193.8 million in Q1 2026 per SRRK's latest filing, from $73.3 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $346.4 million in Q4 2024 and bottomed at -$970000.0 in Q4 2022.
  • The 5-year median for Cash from Financing Activities is $4.7 million (2023), against an average of $63.1 million.
  • Across the five-year window, Cash from Financing Activities plunged 123.66% in 2022 and jumped 86929.52% in 2025, its largest moves.
  • Year by year, Cash from Financing Activities stood at -$970000.0 in 2022, then soared by 10051.44% to $96.5 million in 2023, then jumped by 258.82% to $346.4 million in 2024, then sank by 78.84% to $73.3 million in 2025, then surged by 164.42% to $193.8 million in 2026.
  • Per Business Quant, the three latest SRRK Cash from Financing Activities figures stand at $193.8 million (Q1 2026), $73.3 million (Q4 2025), and $144.5 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 30.14 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 68.63 Mn
4 NuCana 279.75 Bn 279.75 Bn - 9,311.16
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -538.80 Mn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -802.20 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - 238.74 Mn
10 Scholar Rock Holding 6.30 Bn 6.30 Bn - 193.79 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 193.79 Mn
Mar 31, 2026 193.79 Mn
Dec 31, 2025 73.29 Mn
Dec 31, 2025 73.29 Mn
Sep 30, 2025 144.47 Mn
Sep 30, 2025 144.47 Mn
Jun 30, 2025 6.47 Mn
Jun 30, 2025 6.47 Mn
Mar 31, 2025 4.17 Mn
Mar 31, 2025 4.17 Mn
Dec 31, 2024 346.37 Mn
Dec 31, 2024 346.37 Mn
Sep 30, 2024 166,000.00
Sep 30, 2024 166,000.00
Jun 30, 2024 -33,000.00
Jun 30, 2024 -33,000.00
Mar 31, 2024 6.53 Mn
Mar 31, 2024 6.53 Mn
Dec 31, 2023 96.53 Mn
Dec 31, 2023 96.53 Mn